2005
Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST)
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal Of Obstetrics And Gynecology 2005, 192: 387-393. PMID: 15695976, DOI: 10.1016/j.ajog.2004.08.017.Peer-Reviewed Original ResearchConceptsMini-Mental State ExaminationEstrogen therapyCognitive declineNormal Mini-Mental State ExaminationDouble-blind trialSecondary stroke preventionTransient ischemic attackIschemic attackPostmenopausal womenStroke preventionRecent strokeStroke trialsCerebrovascular diseaseWomen's EstrogenEstradiol-17betaState ExaminationCognitive measuresEstrogenWomenNormal functionDomain measuresLess declineTherapyStrokeRisk
2003
Use of Ephedra-containing products and risk for hemorrhagic stroke
Morgenstern LB, Viscoli CM, Kernan WN, Brass LM, Broderick JP, Feldmann E, Wilterdink JL, Brott T, Horwitz RI. Use of Ephedra-containing products and risk for hemorrhagic stroke. Neurology 2003, 60: 132-135. PMID: 12525737, DOI: 10.1212/01.wnl.0000042092.20411.5b.Peer-Reviewed Original Research
1990
Treatment adherence and risk of death after a myocardial infarction
Horwitz RI, Viscoli CM, Donaldson R, Murray C, Ransohoff D, Horwitz R, Berkman L, Horwitz S, Ransohoff D, Sindelar J. Treatment adherence and risk of death after a myocardial infarction. The Lancet 1990, 336: 542-545. PMID: 1975045, DOI: 10.1016/0140-6736(90)92095-y.Peer-Reviewed Original ResearchConceptsRisk of deathTreatment adherenceMyocardial infarctionPoor adherersBeta-Blocker Heart Attack TrialPost-infarction mortalityHeart Attack TrialGood adherersTreatment regimenAttack TrialClinical severitySociodemographic featuresInfarctionAdherersAdherenceDeathMortalityRiskSeverityPlaceboRegimenSmokingPatientsPropranololTrials